CD68, a haematopoietic differentiation marker of the monocyte-macrophage lineage, is expressed in various human malignancies including chronic and acute myeloid leukaemia (AML). While the majority of normal CD34 + cells are negative for CD68 expression, CD34
Introduction
The success of tumour immunotherapy is largely dependent on the choice of target antigen. Tumour-associated antigens, that are targeted by various immunotherapy strategies fall into three categories: viral antigens, products of mutated genes and normal cellular proteins. The latter category, which comprises differentiation antigens, has been extensively exploited for the treatment of solid tumours, such as melanoma and prostate cancer. 1 Self-tolerance to differentiation antigens expressed in non-haematopoietic cells is probably not absolute, providing an explanation for the detection of CTL against these antigens in tumour patients. The use of haemopoietic differentiation antigens, however attractive it may appear for the purposes of targeting cellular immune responses against leukaemic blast cells, is limited by potent tolerogenic effects of haemopoietic cells. Hence, it is likely that autologous T cells specific for haemopoietic differentiation antigens have been deleted in the thymus or rendered unresponsive by peripheral tolerance mechanisms.
In the past few years, we have developed a strategy to circumvent tolerance to self proteins. 2 The allo-restricted strategy is based on the observation that T cell tolerance is self-MHC restricted. Hence, T cells from A2-negative donor individuals can mount CTL responses against epitopes from self-proteins presented by A2 class I molecules. Using this strategy, we have previously identified CTL epitopes in the self-proteins mdm2 and cyclin D1, and shown that the CTL selectively killed tumour cells expressing large quantities of these proteins but not normal cells with physiological expression levels. 2, 3 The purpose of this study was to explore whether the allorestricted strategy can be used to identify CTL epitopes in CD68. CD68, a differentiation marker of haematopoietic cells of the monocyte and macrophage lineage, was found to be produced at elevated levels in a number of human tumours including acute myeloid leukaemia, 4 shwannomas, granular cell tumours 5 and hystiocytomas. 6 We have focused on the identification of CTL epitopes presented by HLA-A2 because this class I allele is present in nearly 50% of Caucasian individuals. We also attempted to identify CTL epitopes in the murine CD68 molecule 7 because this would allow us to develop a murine model to explore CD68-based immunotherapy in vivo.
Materials and methods

Animals
C57Bl/6 (H-2 b ) and BALB/c (H-2 d ) were supplied by the breeding colony of Stolbovaya Animal Laboratories (Russia). Mice were used at the age of 8-10 weeks.
Cell lines
RMA cells (H2 b ) originate from a Rauscher virus-induced C57/Bl6N T cell lymphoma. RMA-S is a TAP2-deficient mutant of the RMA line.
8 T2 is a human TAP-deficient line 9 with low levels of HLA-A2 expression. K562-A2 cells were obtained by electroporation of the human erythroleukaemia cell line K562 with the HLA-A0201 gene. The C1R-A2 line is derived from the human lymphoblastoid cell line C1R by transfection with the HLA-A0201 gene. The hybridoma cell line QS4120 was kindly provided by Prof P Beverley (The Edward Jenner Institute for Vaccine Research, Berks, UK). THP-1 is an HLA-A2-positive human monocytic leukaemiaderived cell line, 10 BV172 is an HLA-A2 positive, CD68-negative acute leukaemia line.
11 ANA-1 is a C57Bl/6-derived (H-2 b ) macrophage cell line, kindly provided by Prof L Varesio (The Edward Jenner Institute for Vaccine Research, Berks, UK).
Patient material
Peripheral blood from leukaemia patients was obtained after informed consent. According to FAB criteria patients were classified as M2 (patient L), M4 (patient D, Dr and A). CD68 expression was confirmed by flow cytometric analysis with anti-CD68 antibodies. Control CD68-negative samples were obtained from two patients with malignant lymphomas with bone marrow involvement (patient V and S) and a T-ALL patient, Au.
Peptides
All peptides were synthesised according to standard solidphase methods and were purified by high performance liquid chromatography (HPLC). The purity and identity of peptides were determined by analytical HPLC and mass-assisted laser desorption ionisation mass spectrometry. The peptides were dissolved at a concentration of 5 nM in DMSO and stored at −20°C until further use.
Peptide binding assay
TAP-deficient cells lines RMA-S and T2 were used to test MHC class I binding of synthetic peptides derived from mouse and human CD68, respectively. 5 × 10 5 cells were incubated overnight in triplicate 96-well plates in 100 l RPMI1640 medium with 5% boiled (to inactivate proteases) FCS containing various concentrations of peptides. Wells without peptides or with the known MHC-binding peptides were used as negative and positive controls. After incubation cells were stained by indirect immunofluorescence using conformation-dependent antibodies, specific for MHC molecules. Supernatants from HB54 and HB117 hybridomas (American Type Culture Collection, ATCC, Rockville, MD, USA) were used to test peptide binding to HLA-A2 molecules; supernatants from Y3 and HB27 lines (ATCC) revealed binding of synthetic peptides derived from mouse CD68 to K b and D b molecules.
Mouse CTL lines and clones
Self-restricted mouse CTL lines were produced by incubation of splenocytes from C57Bl/6 mice in RPMI1640 medium with 10% of selected FCS, glutamine and antibiotics (T cell medium) with the addition of 10 M peptide for 5 days. Cells were harvested and seeded in a concentration of 5 × 10 5 /ml in fresh T cell medium with 10 U/ml interleukin-2 (IL-2), 10 6 /ml irradiated (3000 rad) autologous splenocytes as feeder cells and 10 5 stimulators/ml. Dendritic cell-enriched fraction of autologous splenocytes obtained by gradient centrifugation with 14.5% metrisamide 12 were used as stimulators. Stimulators were incubated with 100 nM of the immunising peptide for 2 h, washed and irradiated (3000 rad) prior to adding to T cell culture. T cell cultures were restimulated every 2 weeks. Peptide-specific cultures were cloned by limiting dilution seeding 0.3, 1 and 3 cells/well in 96-well plates.
Allo-restricted CTL lines and clones were produced as described in Ref. 3 . Briefly, splenocytes from Balb/c mice were stimulated with irradiated (10 000 rad) peptide-loaded RMA-S cells. RMA-S were sensitised by o/n incubation with 100 M peptide in medium with 5% boiled FCS. On day 5 cells were harvested and seeded in 96-well plates in decreasing concentrations starting from 10 4 cell/well using irradiated peptide-loaded RMA-S cells as stimulators and autologous splenocytes as feeder cells. Cultures were tested for specific recognition of immunising peptides and cloned by limiting dilution.
Human CTL lines and clones
Ficoll-separated peripheral blood mononuclear cells (PBMC) from HLA-A2-positive healthy donors were stimulated with 10 M peptides adding peptides to 2 × 10 6 cells per well cultured in 24-well plates. Five days later cells were harvested and plated at a concentration of 2.5 × 10 5 /ml with the addition of 10 6 /ml autologous irradiated PBMC, 2.5 × 10 4 /ml stimulators and 10 U/ml IL-2. Autologous light density fraction cells obtained by density centrifugation of PBMC with 14.5% metrisamide and preincubated with 100 M peptide were used as stimulators. Peptide-specific cultures were cloned by limiting dilution using irradiated peptide-loaded T2 cells (2 × 10 4 cells/well) as stimulators and autologous PBMC (2 × 10 5 cells/well) as feeders. HLA-A2-negative T cell cultures were generated as described in Ref, 3 . Briefly, PBMC from HLA-A2-negative donors were repeatedly stimulated in bulk cultures with T2 cells sensitised by o/n incubation with synthetic peptides in the presence of 10 U/ml IL-2, using autologous irradiated PBMC as feeders. T cell lines were cloned in 96-well plates by limiting dilution. Wells positive for cell growth were tested in a CTL split-well analysis using T2 cells pulsed with immunising or control peptides. The obtained CTL are referred to as clones if the percentage of wells with cell growth did not exceed 30%. T cell clones were restimulated weekly by seeding 2 × 10 5 cell/ml into wells containing 10 6 irradiated feeders, 10 5 /ml stimulators, 10 U/ml IL-2 and 2.5 ng/ml IL-7 (R&D Systems, Minneapolis, MN, USA).
CTL assays
Cytotoxic activity of T cells stimulated with synthetic peptides was analysed on day 5 or 6 after stimulation using CytoTox 96 non-radioactive cytotoxicity assay (Promega, Southampton, UK). The assay was performed according to the manufacturer's instructions. 10 6 RMA-S cells, T2 cells, PBMC from healthy donors or AML patients and tumour cell lines positive or negative for CD68 expression were incubated for 2 h with 100 M synthetic peptides or without peptides, washed in PBS and resuspended in the assay medium (phenolfree RPMI1640 medium with 2% BSA). Cell lines were used at a concentration of 3.5 × 10 3 cells/ml. Peripheral blood cells were used at a concentration of 1.5-3 × 10 4 cells/well. Target cells and serial dilutions of T cells from bulk cultures were incubated in U-bottom 96-well plates for 4-6 h. In order to test sensitivity of peptide-specific T cell clones, target cells were incubated in the wells containing serial dilutions of the immunising or control peptides for 1 h. The ability of human target cells to load peptides was improved by denaturating HLA-A2 molecules on T2 cells with 0.2 M acetic acid and 0.5 N NaCl in H 2 O for 1 min and immediate refolding by neutralisation with RPMI medium in the presence of 3 g/ml human ␤-microglobulin (Sigma, St Louis, MO, USA) and varying concentrations of peptides. Equal amounts of T lymphocytes were added to each well and to control wells. Cytotoxic activity was estimated by the amount of lactate dehydrogenase released from lysed target cells using the equation.
% cytotoxicity ϭ experimental − effector spntaneous − target spontaneous target maximum − target spontaneous × 100
Background was subtracted from each experimental value. THP-1, K562-A2, C1R-A2, ANA-1 and RMA tumour cell lines used for testing specificity of CTL clones were pretreated with 200 U/ml ␥-IFN (R&D Systems) for 48 h prior to CTL assay. Both ␥-IFN-treated and untreated cells were used as targets.
Analysis of CD68 and MHC class I expression
HB54 (specific for and A2 and B7 molecules) and HB117 antibodies (specific for A2 and A28) (ATCC) were used to test 
Results
Search for CTL epitopes in mouse CD68
In order to identify candidate MHC-binding epitopes in the murine CD68 protein, two predictive computer algorithms available on the internet were used [15] [16] [17] (http://syfpeithi.bmiheidelberg.com/Scripts/MHCServer.dll/EpPredict.htm, http:// bimas.dcrt.nih.gov/cgi-bin/molbio/kenFparkerFcomboform).
In total, five peptides were synthesised, three with predicted D b binding activity and two with predicted K b binding activity (see Table 1 
ANA-1 cells (not shown)
. There are at least two possible explanations for the lack of killing of ANA-1 target cells: (1) endogenous CD68 antigen processing did not produce the relevant peptides; (2) the CTL were of low avidity since high avidity CTL were rendered tolerant.
The allo-restricted approach was used in an attempt to generate high avidity CTL responses. Splenocytes from H-2 d BALB/c mice were repeatedly stimulated with peptide-loaded H-2 b antigen-presenting cells. The bulk lines obtained were cloned and analysed in a split-well CTL assay. All three peptides which were immunogenic in the self-restricted setting, were also able to induce allo-restricted T cell clones. At least 20 clones specific for each peptide were expanded and tested for their ability to recognise low concentrations of immunising peptides. Peptide titration experiments were used in order to select CTL clones with the highest avidity. Figure 3a -c shows that CTL sensitivity varied approximately 100-fold, with some clones requiring 1 nanomolar peptide concentrations for target cell lysis, while the more sensitive clones recognised 10 picomolar peptide concentration. However, all clones obtained failed to recognise ANA-1 line (Figure 3d-f) , which expresses CD68 endogenously (Figure 3g ). Hence, endogenous antigen processing of murine CD68 fails to produce the three peptide epitopes, or the CTL avidity is insufficient to recognise low amounts of endogenously produced peptides.
HLA-A2-binding properties of synthetic peptides derived from human CD68
The protein sequence of CD68 was screened for the presence of HLA-A2-binding peptides using the computer algorithms 2023 described above. Among six peptides selected for the study (Table 2) five showed A2-binding in the T2 whole cell stabilisation assay (Figure 4a) . Interestingly, peptide 320-328 which was ranked as an intermediate binder by computer prediction, showed high affinity A2-binding in a T2-binding assay, comparable to that of the human papilloma virus-derived positive control peptide. Two 9-mer peptides with the highest predictive scores and one 10-mer peptide bound to HLA-A2 molecules with intermediate affinity.
CTL generation against HLA-A2-binding, CD68-derived peptides
PBMC from HLA-A2 + donors were repeatedly stimulated with autologous DC loaded with CD68-derived peptide. The lines obtained showed no specificity against target cells sensitised with the immunising peptides in cytotoxicity assays. A control A2-binding peptide (cyc101) was able to induce specific CTL lines under the same conditions (data not shown). These results were reproduced in five independent experiments using PBMC from different donors. This is consistent with the absence of CTL against these peptides in the self-A2-restricted repertoire, possibly due to tolerance.
Hence, the allo-restricted approach was explored. PBMC from HLA-A2
− donors were stimulated with A2-positive T2 cells loaded with A2-binding peptides. Cloning of the bulk lymphocyte cultures stimulated with peptide 329-337 revealed clones that specifically lysed target cells loaded with the immunising peptide but not the control HLA-A2-binding peptide (Figure 4b-d) . Other CD68-derived peptides were unable to induce specific responses (not shown). Twenty-one 329-337-specific clones of cytotoxic T cells derived from PBMC from different donors were generated. These CTL were highly peptide specific when tested against peptide-coated TAP-deficient T2 target cells (Figure 4c and d) , and titration experiments showed that the most sensitive clones required approximately 50 pM peptide for target cell recognition (Figure 5a ). The list of target cells, used to define specificity of the peptide-induced clones obtained is presented in Table  3 . The CTL were tested against the lymphoblastoid cell line C1R-A2 to determine whether they showed non-specific killing against TAP-positive targets expressing A2 molecules loaded with endogenously produced peptides. Figure 5b shows that the CTL showed no significant killing against C1R-A2 target cells. No recognition of HLA-A2
+ peripheral blood cells from lymphoma patients negative for CD68 expression Table 2 Predicted characteristics and HLA-A2 binding properties of peptides, derived from human CD68 
Figure 4
HLA-A2 binding and CTL induction by peptides derived from human CD68. (a) The ability of the synthetic peptides to stabilise A2 molecules on TAP-deficient T2 cells measured using conformation-dependent A2-specific antibodies. Peptide affinity was compared to that of the control peptide E7 83-96; (b) split-well analysis of CTL clones, induced by peptide 329-337; (c and d) specificity of CTL clones 1 and 2, respectively. T cells recognised T2 cells loaded with the immunising peptide (filled columns) but not the control peptide (empty columns).
was detected (Figure 5c ). Next, we tested the CTL against A2-positive, CD68-expressing leukaemia cell lines. Figure 5d and e demonstrates that the CTL displayed low-level killing against THP-1 leukaemia cells and the A2-transfected K562-A2 cells. The killing of K562-A2 leukaemia cells was A2-restricted, since untransfected K562 cells were not killed. ␥-IFN treat- Table 3 CTL recognition of target cells by CTL clones, induced with 329-337 peptide Target cells  Origin  HLA-A2  CD68  Recognition by antiexpression  expression  329-337 
Discussion
In the present study the haemopoietic cell differentiation marker CD68 has been chosen for targeting anti-tumour immune response. The antigen choice was prompted by the pattern of its expression, which is restricted to differentiated haemopoietic and leukaemic cells. 4 The vast majority of normal CD34
+ haemopoietic precursors are CD68-negative, whereas AML CD34 + blasts are CD68-positive. Hence, CD68 is an interesting target for immunotherapy of AML, particularly in the allo-restricted setting and in patients who undergo allogeneic stem cell transplantation.
The attempts to identify CTL epitopes in the murine CD68 molecule were unsuccessful. Although self-and allo-restricted CTL were highly specific for K b and D b presented peptide epitopes of CD68, they did not recognise murine cells expressing CD68 endogenously. It is possible, that the isolated CTL were not of sufficient avidity to recognise limited amounts of peptides produced in CD68-expressing target cells. Titration experiments indicated that the best allo-restricted CTL clones isolated in this study recognised target cells coated with approximately 10 pM of CD68 peptides. In a previous study we isolated allo-restricted CTL clones against a peptide derived from the tumour-associated protein mdm-2 that recognised femtomolar concentrations of peptide. 2 These high avidity CTL efficiently recognised mdm-2-expressing tumour cells. It is likely that the CD68-specific CTL in this study were not sufficiently sensitive to recognise limited amounts of endogenously produced peptides.
Five HLA-A2-binding CD68-derived peptides were unable to induce specific responses in PBMC cultures of HLA-A2-positive donors. The results are consistent with the suggestion that tolerance may result in the absence of specific T cell precursors in the T cell repertoire of HLA-A2-positive donors. In order to circumvent unresponsiveness to CD68-derived peptides, an attempt has been made to generate allo-restricted T cells by stimulating PBMC from HLA-A2-negative donors. This approach has recently been proved to be efficient both for identification of CTL epitopes in the tumour-associated antigen mdm-2 in a mouse and human system, and against the human Wilms tumour antigen 1.
2,18 Peptide 329-337 induced peptide-specific CTL responses, and the obtained clones required approximately 50 pM concentrations of peptides for target cell sensitisation. This is similar to the sensitivity of the murine CTL described above. However, unlike the murine CTL, the human CTL displayed killing of CD68-expressing leukaemia cell lines (THP-1 and K562-A2) and blast cells derived from HLA-A2-positive AML patients. The inefficient killing of the human leukaemia cells is most easily explained by limiting amounts of endogenously produced CD68 peptides. Indeed, killing of AML blasts was enhanced after loading the AML cells with additional exogenously supplied CD68 Leukemia peptides. The killing of A2-expressing target cells was dependent upon endogenous CD68 expression, since CD68-negative C1R-A2 and BV173 targets were not recognised. No specific killing was observed when CD68
− cells from HLA-A2-positive patients were used as targets in CTL assays.
In summary, this study provides evidence that CD68 epitopes expressed by leukaemia cells may serve as a target for leukaemia-reactive CTL. The data suggest that efficient killing of leukaemia cells is critically dependent upon the isolation of high avidity CTL clones. Such CTL are most likely deleted from the self-restricted T cell repertoire. It has been demonstrated that peptide epitope presentation of tumour-associated antigens by host tumour cells can induce epitope shift in the autologous T cell repertoire. Thus, no reactivity to an HLA-A2-restricted SV40 Tag epitope, dominant in normal donors, was observed in A2-positive mesothelioma patients. 19 Peptide epitope shift is unlikely to affect the allo-restricted CTL response since the relevant peptides are not presented by the HLA-A2 molecules of the responder. High avidity allo-restricted CTL may be useful in the context of HLA mismatched allotransplantation for adoptive immunotherapy of patients with minimal residual disease. Alternatively, allo-restricted CTL can provide a source of T cells receptors for transfer into patient T cell for generation of autologous leukaemiareactive lymphocytes. 20 
